PMID- 34104203
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Mulberroside A from Cortex Mori Enhanced Gut Integrity in Diabetes.
PG  - 6655555
LID - 10.1155/2021/6655555 [doi]
LID - 6655555
AB  - BACKGROUND: Diabetic endotoxemia has been recognized as one of the hallmarks of 
      type 2 diabetes mellitus (T2DM). Recent findings suggest that gut leak plays a 
      pivotal role in diabetic endotoxemia. Cortex Mori (CM) has been widely applied in 
      China to ameliorate development of T2DM, but its effect on endotoxemia is 
      unknown. METHODS: The study was constructed with two parts: (1) in vivo study of 
      CM on diabetic endotoxemia in db/db mice. Eight C57BL/6 mice were set as normal 
      control; (2) in vitro study of mulberroside A (MBA) from CM on diabetic 
      endotoxemia. Potential mechanism of MBA on ameliorating diabetic endotoxemia was 
      also explored. RESULTS: The present study found that CM water extract decreased 
      levels of blood glucose, ameliorated liver and renal damage in db/db mice, and 
      ameliorated diabetic endotoxemia (p < 0.01). We also found that the water extract 
      enhanced gut integrity and decreased gut inflammatory protein ICAM-1 expression 
      in db/db mice as detected by H&E staining and immunohistochemistry methods. In 
      the in vitro study, MBA decreased levels of MDA and ROS induced by LPS (p < 0.01) 
      and enhanced the integrity of gut epithelial barrier (p < 0.01). CONCLUSIONS: We 
      found that Cortex Mori and its active component mulberroside A could ameliorate 
      diabetic endotoxemia by preserving gut integrity.
CI  - Copyright (c) 2021 Yinyan Xu et al.
FAU - Xu, Yinyan
AU  - Xu Y
AUID- ORCID: 0000-0002-8905-363X
AD  - Department of Pharmacy, Women's Hospital of Nanjing Medical University, Nanjing 
      Maternity and Child Health Care Hospital, Nanjing 210004, Jiangsu, China.
FAU - Guo, Hengli
AU  - Guo H
AD  - Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese 
      Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, 
      Macao SAR 999078, China.
AD  - Department of Traditional Chinese Medicine, Zhuhai Maternal and Child Health 
      Hospital, Zhuhai 519000, Guangdong, China.
FAU - Zhao, Tingting
AU  - Zhao T
AD  - Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese 
      Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, 
      Macao SAR 999078, China.
FAU - Fu, Jing
AU  - Fu J
AUID- ORCID: 0000-0002-3619-4164
AD  - Department of Pharmacy, Women's Hospital of Nanjing Medical University, Nanjing 
      Maternity and Child Health Care Hospital, Nanjing 210004, Jiangsu, China.
FAU - Xu, Youhua
AU  - Xu Y
AUID- ORCID: 0000-0002-3258-013X
AD  - Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese 
      Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, 
      Macao SAR 999078, China.
LA  - eng
PT  - Journal Article
DEP - 20210520
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8159636
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/06/10 06:00
MHDA- 2021/06/10 06:01
PMCR- 2021/05/20
CRDT- 2021/06/09 06:44
PHST- 2020/12/31 00:00 [received]
PHST- 2021/04/07 00:00 [revised]
PHST- 2021/04/29 00:00 [accepted]
PHST- 2021/06/09 06:44 [entrez]
PHST- 2021/06/10 06:00 [pubmed]
PHST- 2021/06/10 06:01 [medline]
PHST- 2021/05/20 00:00 [pmc-release]
AID - 10.1155/2021/6655555 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 May 20;2021:6655555. doi: 
      10.1155/2021/6655555. eCollection 2021.